Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ep 141: From EMPA-REG to Clinical Practice: Mastering SGLT2 Inhibitors in Modern Cardiology
Added: 8 months ago
In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Shelley Zieroth, Professor of Medicine, clinician-scientist, and advanced heart failure and transplant cardiologist in Winnipeg, Canada. As we mark the 10-year anniversary of the landmark EMPA-REG OUTCOME trial, Dr Zieroth provides a comprehensive update on how SGLT2 inhibitors have revolutionized cardiovascular care.Dr Zieroth… View more

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Hiroaki Shimokawa
Job title: Professor and Chairman, Division of Cardiovascular Medicine
Dr. Shimokawa graduated from Kyushu University in 1979 and obtained MD and PhD degrees at the University. He studied at the Mayo Clinic in 1985-1987 and was appointed as an assistant professor at Kyushu University in 1991, and then associate professor in 1995. In 2005, he was appointed as the professor and chairman of the Department of Cardiovascular Medicine, Graduate School of Medicine, Tohoku… View more
Antoni Bayés-Genís
Research Area(s) / Expertise: Job title: Head of the Cardiology Department
Antoni Bayés-Genís is Head of the Heart Institute at the University Hospital Germans Trias i Pujol in Barcelona, and Professor of Cardiology at the Universitat Autònoma de Barcelona in Barcelona, Spain.Prof Bayés-Genís is an expert on biomarker, including natriuretic peptides ST2 and neprilysin, having lectured on the subject at numerous international meetings and generated research data that… View more
DrPaolo Canova, MD obtained his medical degree with full honours at Milan-Bicocca University in 2008. During his studies he won a scholarship for a cooperation and development project at “St. Mary’ s Lacor Hospital” (Uganda) and completed a clinical fellowship in Internal Medicine and Cardiology at the “Hospital Universitario Marques de Valdecilla” in Santander (Spain). Between 2009 and 2014… View more
Mavacamten Reduces Biomarkers in nHCM: ODYSSEY-HCM Data
Added: 4 months ago Source:  Radcliffe Cardiology
An exploratory analysis of the ODYSSEY-HCM trial has shown that mavacamten significantly reduces key cardiac biomarkers in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), a condition with no approved therapies.¹ While the main trial did not meet its primary endpoints of improving functional capacity or patient-reported health status, these biomarker findings suggest a… View more

Heart Failure
Mauro Biffi
Job title: Clinical Cardiologist and Director of Electrophysiology
Dr Mauro Biffi is a Clinical Cardiologist and Director of Electrophysiology at Sant’Orsola-Malpighi Polyclinic, Bologna, IT.He is also a tutor at the Cardiology School of Bologna University and at several European training facilities. His main areas of interest are arrhythmias and heart failure. Dr Biffi has participated in international clinical trials of pharmacological and non… View more
Luigi Di Biase
Research Area(s) / Expertise: Job title: Section Head of Electrophysiology
Prof Luigi Di Biase is the Section Head of Electrophysiology at the Montefiore Medical Center in the Bronx, NY, US. He graduated summa cum laude fromUniversity of Bari's cardiology residency in 2000, and completed a master's degree of electrophysiology and cardiac pacing at theUniversity of Insubria in Varese in 2006. Prof Di Biase’s research focuses on cardiology and electrophysiology with… View more
Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from the HFA 2024
Author(s): Ahmad Masri , Added: 1 year ago
Recorded during HFA 2024, Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, collaborate to explore the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive… View more

Guidelines & Statements

Heart Failure
Optimized Pacing Eases oHCM Symptoms in EMORI-HCM Trial
Added: 2 months ago Source:  Radcliffe Cardiology
For patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the net effect of right ventricular pacing (RVP) has been variable. A new trial suggests that personalising the therapy by electromechanically optimising the atrio-ventricular delay (AVD) can provide a net benefit for symptoms and exercise capacity.¹Right ventricular pacing can reduce the left ventricular outflow tract… View more

Electrophysiology & Arrhythmia

Heart Failure